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The distribution and adverse eﬀects, especially to optic and acoustic nerves, of cobalt released from a hip arthroplasty and its
association with albumin were studied. The analysis of cobalt was performed in plasma, whole blood, urine, and cerebrospinal
ﬂuid by inductively coupled plasma mass spectrometry (ICP-MS). The fraction of albumin binding the metal was determined by
colorimetric assay using dithiothreitol (DTT). In all the biological matrices very high levels of cobalt were measured, but contrary
to expected, a higher concentration in whole blood than in plasma was observed. The determination of altered albumin conﬁrmed
this hypothesis. This evidence might indicate an alteration in the binding of cobalt to albumin and a consequent increase in the
concentration of the diﬀusible (free) fraction of the metal. This appears an interesting starting point for further investigations
for identifying and better understanding cobalt neurotoxicity, apparently not so frequent in occupational medicine and clinical
practice.
1.Introduction
Last year we reported the case of a 58-year-old woman
with high concentration of cobalt released from her hip
arthroplasty. The woman presented a selective II and VIII
cranial nerves impairment and mild distal sensory-motor
disturbances, and some months later she became deﬁnitely
blind, severely deaf, and wheel-chair bounded due to severe
limbs motor weakness [1].
During surgery of prosthesis removal of a massive
inﬁltration of periprosthesis tissues by metallic debris (met-
allosis) became evident.
The patient has undergone chelation therapy with
ethylenediaminetetraacetic acid (EDTA) in order to reduce
the cobalt body burden.
In the scientiﬁc literature there are only ﬁve other cases
of severe adverse eﬀects on nervous system associated with
cobalt released from prosthesis [2–6].
Moreover, cobalt neurotoxicity for acoustic and optic
nerves has been reported following occupational exposures
tothemetal[7,8]or,fewdecadesago,afteroralintakeduring
therapy of refractory anaemia [9–11].
Cobalt concentrations in biological ﬂuids have been
investigated in subjects with prosthesis [12–14], but the
kinetics of released metal ions is not adequately known, due
to the lack of information about amount and rate of release
from hip surface, about the solubility of released ions and or
about the fraction phagocyted by macrophages and the role
of metal deposition-storage mechanisms [15–17].
The distribution of cobalt in the body is also inﬂuenced
by binding to the plasma proteins. Albumin has been
indicated to be a physiological carrier of cobalt ions in old
a n dm o r er e c e n ts t u d i e s[ 18, 19].
The cobalt binding to albumin has been studied because
the base of the “Albumin Cobalt Binding test” (ACB test)
approved by the Food and Drug Administration for evalu-
ating myocardial ischemia.2 ISRN Hematology
Ischemia modiﬁed albumin (IMA) is a form of human
serum albumin in which the N-terminal amino acids have
been altered so as to be unable to bind transition metals [20].
However, other pathologies such as trauma, scleroder-
mia, diabetes, bacterial or viral infections, end-stage renal
disease, liver cirrhosis, brain ischemia, peripheral arterial
disease, and cancer are able to inﬂuence the binding site
of cobalt in albumin [21–26]. In addition there are also
evidences of possible genetic variants of human serum
albumin, particularly structural changes at the N-terminus
abolish transition metals binding [27, 28].
The direct measurement of cobalt levels in biological
matrices and protein binding of this clinical case may be
useful in understanding eﬀects and variability of cobalt
neurotoxicity.
2.MaterialandMethods
2.1. Cobalt Analysis. Cobalt in blood, plasma, urine, and
cephalorachidian ﬂuid was measured using an inductively
coupled-plasma mass spectrometry (ICP-MS, ELAN DRC II,
Perkin Elmer, Waltham, USA) equipped with Dynamic Cell
Reaction. The detailed method is described in a our previous
paper [29].
The samples of plasma and blood were diluted with
Triton X-100 0.05%, while for urine and cephalorachidian
ﬂuid was used bidistilled water, tracepur for inorganic
trace analysis (Merck KgaA). The calibration standards were
prepared by standard solutions of single elements ranging
from 0.5µg/L to 1000µg/L cobalt (in HNO3 2% mono
elemental standard solution Carlo Erba Reagenti, Milano,
Italy).
The accuracy of the method was assessed using spe-
ciﬁc certiﬁed materials for diﬀerent matrices 1A/B (blood
samples), 11A/B (plasma) 2A/B (urine), all from the Ger-
man Society of Occupational and Environmental Medicine
(Erlangen, Germany). The sample solutions were pumped
in the spray chamber by a peristaltic pump detecting mass
59(Co).
The accuracy of methods for the determination of cobalt
in blood and urine was 95%, whereas it was 97% for
plasma. Method precision was 6.1 and 6.9% for blood and
plasma determinations, respectively, whereas in the case of
urine precision was 4.1%. For each matrix, the LODs were
determined as three SD of the background signal. The LOD
was 0.02µg/L for Co–B and Co–P, and 0.05µg/L for Co–U.
2.2. IMA Determination. The concentration of IMA can be
determined by addition of known amount of cobalt to serum
orplasmaspecimenandmeasurementoftheunboundcobalt
by colorimetric assay [20, 23, 30–32].
To remove the interference of EDTA, the plasma was
pretreated with calcium chloride (CaCl2 x2 H 2O; Sigma-
Aldrich); the combination of sample and reagent pre-
treatment was then centrifuged at 1000–1200g for 10
minutes without mixing the two components [33].
Plasma was incubated with a cobalt chloride solu-
tion (Sigma-Aldrich, CoCl2·6H2O; 1g/L, 10 minutes) and
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Figure 1: Levels of cobalt (µg/L) in plasma (CoP), whole blood
(CoB),andcephalorachidianﬂuid(CoL)inwomanwithprosthesis.
The normal values are CoP 0.1–0.6µg/L; CoB 0.05–2.7µg/L; CoL
0.05–0.15µg/L.
dithiothreitol (Sigma-Aldrich; 1.5g/L, 2 minutes) before
dilution in saline solution (0.9% NaCl) and measurement at
470nm in a spectrophotometer (UV-Vis spectrophotometer
Cary 50, Varian, Palo Alto, USA). IMA was calculated
from the diﬀerence between samples measured with and
without dithiothreitol and reported in mean absorbance
units (ABSU). Bar-Or et al. [31] showed that values greater
than 0.400 ABSU indicate lower cobalt binding and values
equal or lower than 0.400 ABSU higher cobalt binding.
2.3. Statistical Analysis. Data were analyzed by the SPSS 16.0
for Windows statistical package.
The distributions, assessed by the one-sample Kolmog-
orov-Smirnov test, were normal for plasmatic and hematic
cobalt in controls and for IMA in both groups.
The trend of cobalt distribution in woman’s plasma and
blood and in CoB/CoP ratio was assessed by Ordinary Least
Square (OLS).
The range of repeated measures of cobalt concentrations,
ratio CoB/CoP and IMA in woman with prosthesis were
compared with the arithmetic means of healthy and unex-
posed subjects.
3. Results and Discussion
Trend of plasma, whole blood, and urine cobalt concentra-
tions are reported in Figures 1 and 2. Cobalt basal levels were
very high (549µg/L in whole blood; 260µg/L in plasma),
after the chelation therapy the levels decreased by 70% in
whole blood and 61% in plasma. A further reduction occurs
after the prosthesis removal (94µg/L in whole blood and
64µg/L in plasma).
The current (14 months after removal) cobalt levels
remained higher than reference values (33.9 versus 0.05–
2.7µg/L in blood; 28.5 versus 0.1–0.6µg/L in plasma).ISRN Hematology 3
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Figure 2: Levels of cobalt in urine (CoU) in µg/L in woman with
prosthesis. The normal values are 0.1–1.5µg/L.
Table 1: Ratio of whole blood cobalt (CoB)/plasma cobalt (CoP)
in present study (repeated measures), workers exposed to cobalt,
and ratio reported in a study of Walter et al. [34]. mean ± standard
deviation.
N
◦ CoB/CoP CoB (µg/L) CoP (µg/L)
Present study 61 1.73 ± 0.38 196.12 ± 134.45 106.36 ± 57.49
Workers
exposed to
cobalt
23 0.90 ± 0.40 3.20 ± 1.52 3.86 ± 1.84
Walter et al.,
[34]
29 0.82
In the urine cobalt was rapidly and in great extent
eliminated after a chelation therapy, the rate of excretion
was2173µg/Landstabilizedaround200µg/Lafterprosthesis
removal.
The cobalt in the cephalorachidian ﬂuid was determined
beforechelationandremovaloftheprosthesis(11.4µg/Land
10.1µg/L) and two days after (5.4 and 2.6µg/L); the normal
values ranged between 0.05–0.15µg/L.
In spite of these high levels a clear improvement of
clinical evidence for most adverse eﬀects to nervous system,
except the visual function, was seen.
Theinvestigationofcobaltdistributioninbloodfractions
showed, contrary to the expected, that most of the cobalt was
in whole blood than in plasma.
Normally most of the cobalt is found in the serum and
plasma with lower concentrations in the red blood cells
(RBC); the whole blood levels are between those of the RBCs
and the plasmatic fraction [34].
The ratio CoB/CoP is diﬀerent when considering dif-
ferent kind of metal exposures, in Table 1 were reported
the ratio of workers exposed to cobalt during hard metals
production (unpublished data) and a collection of samples
from patients after hip arthroplasty [34].
A greater distribution of cobalt in whole blood than
in plasma may indicate an alteration in the binding of
cobalt to plasma proteins and an increased concentration of
nonprotein-bound cobalt.
1.5
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Figure 3: Cobalt-HSA binding absorbance (ABSU) in the woman
with prosthesis (repeated measures on diﬀerent days) (A) and in
healthy unexposed subjects (B) (mean).
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Figure 4: Correlation between ratio blood cobalt (CoB)/plasma
cobalt (CoP) and ischemia modiﬁed albumin (IMA), expressed in
absorbance units.
IMA was measured in diﬀerent samples of patients
in study and in healthy unexposed subjects, IMA values
signiﬁcantly higher than controls seem to conﬁrm this
hypothesis (Figure 3).
According to Bar-Or [31] the absorbance units (ABSU)
greater than 0.4 indicate a reduced cobalt binding to
albumin.
I M A ’ sv a l u e sa n dr a t i oo fC o B / C o Ps h o w e dag o o d
correlation (r2 = 0.6325) (Figure 4); on the contrary, no
correlation has been demonstrated between the values of
IMA and the concentrations of cobalt in blood or in plasma.
Cobalt in blood and plasma follows a deﬁned decreasing
trendwhiletheratioofCoB/CoPdoesnotfollowanyspeciﬁc
trend.
Critical points of this hypothesis have been considered;
the possibility that in our conditions the albumin binding
site could be only saturated by high amount of cobalt and
not altered is disproved by the fact that altered albumin
(IMA 0.92 and 1.17 ABSU) corresponds both to high and
lower cobalt blood concentrations (415 and 38µg/L, resp.),
excluding a possible interference of cobalt concentration on
colorimetric measure.4 ISRN Hematology
The percentage of blood albumin on total proteins was
monitored during the hospitalization period and was 55.68
± 9.57% (normal range of laboratory 55–69%).
The alteration of N-terminal binding site of human
albumin may be the cause of the reversed CoB/CoP ratio
and the consequent greater amount of cobalt in an avail-
able form for higher distribution and interaction into the
cells.
Nonprotein-bound metal can enter cells through a
promiscuous metal transporter, divalent metal transporter
1( D M T 1 )[ 35, 36], that is known to actively transport
iron, zinc, manganese, cobalt, cadmium, copper, and lead,
via a proton-coupled mechanism [37]. DMT1 is predicted
to have 12 transmembrane segments and to be expressed
in neurons, allowing the incorporation of metals from
the extracellular environment and/or from the recycling
endosomes.
Howitt et al. [38] showed that human neurons in culture
were susceptible to metal toxicity in cellular assays involving
increasing concentrations of environmental iron and cobalt.
They have identiﬁed DMT1 as the key player in the entry of
metal ions in the brain.
In our case an high concentration of free cobalt in the
whole blood could be available to interact with DMT1 and
becoming the cause of the neurological eﬀects.
The concentration of cobalt in cerebrospinal ﬂuid mea-
sured before chelation and before prosthesis removal showed
a massive amount of cobalt (11.4µg/L), that corresponds to
a 2.37CoB/CoP ratio.
An alteration of the bound with the main plasma protein
resulting in a greater amount of free cobalt may be the cause
of the not frequently neurologic symptoms reported in the
scientiﬁc literature for cobalt intoxication.
Some authors suggest that the alteration of binding site
of albumin could be the result of acidosis, reduced oxygen
tension, and the generation of free radicals [39, 40]a n d
this conditions could be caused by cobalt and chromium
constantly released from the prosthesis.
In addition genetic variants of human serum albumin
have been reported, each of these variants has been classiﬁed
on the basis of the structural changes at the N-terminus that
abolish transition metal binding [41].
Another aspect to consider is the possible inﬂuence of
diabetes. Our patient implanted with hip prosthesis was
suﬀering from type 2 diabetes.
Many authors reported higher levels of IMA in diabetic
patients, and they suggest that the plasmatic albumin of
diabetic patients was modiﬁed for the chronic hypoxia
conditions provoked mainly by hyperglycemia and oxidative
stress in diabetes [25, 41].
Ukinc et al. [42] reported that diabetic patients without
cardiovascular disease have a higher serum IMA levels
compared to healthy controls.
Diabetes may have been a contributory cause of the
alteration of albumin that in the state of cobalt intoxication
was not able to correctly bound it favoring the increase in the
haematic fraction.
4. Conclusion
Amongallthepatientswithextremelyhighcobaltconcentra-
tions in blood or urine, only few develop a severe neurologic
syndrome. The reason is still unclear and, even if it is certain
that cobalt can cause potential serious eﬀects on human
centralnervoussystem,littleisknownaboutthemechanisms
through which this metal can cause neurotoxicity to optic
and acoustic nerves.
Wehavetriedtoexplaintheanomalousreactiontocobalt
in diﬀerent ways and an alteration of plasma protein with
a consequent more active fraction seems to be the most
plausible hypothesis for the neurological symptoms.
A possible explanation for the symptoms may be
the altered albumin binding capacity and the consequent
increase of the free form of cobalt in the blood.
The decreased linkage to albumin for cobalt generates
IMA and increases the concentration of biologically active
free cobalt. The free cobalt can then interact with speciﬁc
protein carriers to the cellular targets of the central nervous
system.
The cause of albumin alteration is not clear, we hypoth-
esize an inﬂuence of several factors, which in this speciﬁc
situation are the generation of free radicals by cobalt, a
genetic predisposition or a possible inﬂuence of diabetes.
We hope that our study can be the starting point for
further studies on the neurological eﬀects related to the
toxicity of cobalt.
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